Cyclosporins

ApprovedSmall molecule

Merck & Co.

Cyclosporins is one of 236 small molecule programs targeting Keratoconus. It is currently in Approved.

Indications

Total Trials

Active Trials

235

Competitors

Pipeline

Status by Indication[3][1]

Indication

KeratoconusActive, not recruiting

Kidney TransplantActive, not recruiting

Bone Marrow TransplantationActive, not recruiting

Sjogren SyndromeActive, not recruiting

Severe Aplastic AnemiaActive, not recruiting

Breast CancerActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

PsoriasisActive, not recruiting

Membranous NephropathyActive, not recruiting

KeratoconusPreclinical

Active, not recruiting

Kidney TransplantPhase 2

Active, not recruiting

Bone Marrow TransplantationPhase 2

Active, not recruiting

Sjogren SyndromePhase 3

Active, not recruiting

Severe Aplastic AnemiaPreclinical

Active, not recruiting

Breast CancerPhase 1

Active, not recruiting

Rheumatoid ArthritisPhase 1

Active, not recruiting

PsoriasisPreclinical

Active, not recruiting

Membranous NephropathyApproved

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Cyclosporins

Merck & Co.

Approved

1 2

Halaven

Eisai

Preclinical

38 3

Trodelvy

Gilead

Preclinical

37 4

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 7

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 8

Avastin

Roche

Preclinical

4 9

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 10

Zoladex

Luye Pharma Group Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2034

Phase 2Active, not recruiting

Bone Marrow Transplantation

NCT01659606

Clinical

Trials by Indication[1]

Recurrence1 trial

Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Recurrence

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT01079988·41 enrolled

Keratoconus1 trial

Identification and Validation of Functional Biomarkers for Keratoconus

Unknown status·NNarayana Nethralaya··NCT01746823·200 enrolled

Severe Aplastic Anemia1 trial

Clinical Study of Non Severe Aplastic Anemia Treated With Cyclosporine, Androgen and Levamisole

Unknown status·SShengyun Lin·N/A·NCT03218657·248 enrolled

Efficacy1 trial

Efficacy Study of FK-506 and Cyclosporine in Vernal Keratoconjunctivits (VKC)

Completed·SSiriraj Hospital·Phase 2/3·NCT01068054·24 enrolled

Breast Cancer1 trial

Cyclosporine A in Combination With Nab-Paclitaxel in Patients With Metastatic Breast Cancer

Completed·NNorthwestern University·Phase 1·NCT00983424·14 enrolled

9 more indications

Treatment1 trial

Alipogene Tiparvovec for the Treatment of LPLD Patients

Withdrawn·UUniQure Biopharma B.V.·Phase 2·NCT02904772

Clinical Trial1 trial

Clinical Trial To Determine The Effectiveness And Safety Of Topical Insulin In Dry Eye

Completed·BBarbara Burgos Blasco·Phase 4·NCT05692739·116 enrolled

Kidney Transplant1 trial

Rapamycin and Regulatory T Cells in Kidney Transplantation

Completed·FFondazione IRCCS Policlinico San Matteo di Pavia·Phase 2·NCT01014234·56 enrolled

Psoriasis1 trial

Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis

Completed·JJochen Schmitt.··NCT01812954·1 enrolled

Interaction1 trial

Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin

Completed·AAkebia Therapeutics·Phase 1·NCT03801746·40 enrolled

Bone Marrow Transplantation1 trial

Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita

Active, not recruiting·—·Phase 2·NCT01659606·40 enrolled

Sjogren syndrome1 trial

Comparing Effect of Topical Tacrolimus 0.03% Versus Cyclosporine 0.05% in Dry Eyes of Secondary Sjogren Syndrome

Completed·PPavly Moawd·Phase 3·NCT03865888·60 enrolled

Membranous Nephropathy1 trial

Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy

Unknown status·GGuangdong Provincial People's Hospital·Phase 4·NCT03170323·128 enrolled

Rheumatoid Arthritis1 trial

Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism

Terminated·NNorthwestern University·Phase 1·NCT00282412·4 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Cyclosporins. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cyclosporins compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cyclosporins. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Merck & Co.

Cyclosporins

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2034

Trials by Indication[1]

Recurrence1 trial

Keratoconus1 trial

Severe Aplastic Anemia1 trial

Efficacy1 trial

Breast Cancer1 trial

Treatment1 trial

Clinical Trial1 trial

Kidney Transplant1 trial

Psoriasis1 trial

Interaction1 trial

Bone Marrow Transplantation1 trial

Sjogren syndrome1 trial

Membranous Nephropathy1 trial

Rheumatoid Arthritis1 trial

References

Drug Info

Quick Facts

Related News